Ritter Pharmaceuticals, Inc. develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RTTR
CUSIPN/A
Phone310-203-1000
Debt
Debt-to-Equity RatioN/A
Current Ratio23.86
Quick Ratio23.86
Price-To-Earnings
Trailing P/E Ratio-0.58
Forward P/E Ratio-1.02
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.03 per share
Price / Book0.98
Profitability
EPS (Most Recent Fiscal Year)($5.00)
Net Income$-7,860,000.00
Net MarginsN/A
Return on Equity-136.12%
Return on Assets-85.45%
Miscellaneous
Employees9
Outstanding Shares5,020,000
Ritter Pharmaceuticals (NASDAQ:RTTR) Frequently Asked Questions
What is Ritter Pharmaceuticals' stock symbol?
Ritter Pharmaceuticals trades on the NASDAQ under the ticker symbol "RTTR."
When did Ritter Pharmaceuticals' stock split? How did Ritter Pharmaceuticals' stock split work?
Ritter Pharmaceuticals's stock reverse split on the morning of Friday, March 23rd 2018. The 1-10 reverse split was announced on Thursday, March 22nd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 22nd 2018. An investor that had 100 shares of Ritter Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.
How were Ritter Pharmaceuticals' earnings last quarter?
Ritter Pharmaceuticals Inc (NASDAQ:RTTR) posted its quarterly earnings results on Tuesday, May, 15th. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.40) by $0.01. View Ritter Pharmaceuticals' Earnings History.
What price target have analysts set for RTTR?
4 brokerages have issued 12-month price targets for Ritter Pharmaceuticals' shares. Their forecasts range from $15.00 to $20.00. On average, they anticipate Ritter Pharmaceuticals' share price to reach $16.6667 in the next year. View Analyst Ratings for Ritter Pharmaceuticals.
What are Wall Street analysts saying about Ritter Pharmaceuticals stock?
Here are some recent quotes from research analysts about Ritter Pharmaceuticals stock:
- 1. HC Wainwright analysts commented, "We note that the company recorded a net loss per share of $0.41, roughly in-line with our projection of a net loss per share of $0.42. Investors should note that the prior quarterly numbers reflect pre-split calculations. Ritter conducted a 1- for-10 reverse stock split in March 2018. In the wake of these results and in anticipation of the presentation of two posters on aspects of the Phase 2b data from the previously-concluded trial of RP-628—both clinical impact and background on the patient evaluation tool used in the study—at the Digestive Disease Week (DDW) medical conference in Washington, DC at the beginning of June, we reiterate our Buy rating and 12-month price target of $15.00 per share on RTTR. RP-G28 slated to enter pivotal development near term." (5/29/2018)
- 2. According to Zacks Investment Research, "Ritter Pharmaceuticals, Inc. is involved in developing therapeutic products to treat inflammatory, gastrointestinal and metabolic diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which is under development for the reduction of symptoms associated with lactose intolerance. Ritter Pharmaceuticals, Inc. is headquartered in Los Angeles, California. " (5/8/2018)
Who are some of Ritter Pharmaceuticals' key competitors?
Some companies that are related to Ritter Pharmaceuticals include Novus Therapeutics (NVUS), Alimera Sciences (ALIM), Helix Biopharma (HBPCF), vTv Therapeutics (VTVT), IntelGenx Technologies (IGXT), Zosano Pharma (ZSAN), OASMIA PHARMACE/ADR (OASM), AzurRx BioPharma (AZRX), Acerus Pharmaceuticals (TRLPF), Addex Pharmaceuticals (ADDXF), Moleculin Biotech (MBRX), Imprimis Pharmaceuticals (IMMY), Q BioMed (QBIO), Celsion (CLSN) and Onconova Therapeutics (ONTX).
Who are Ritter Pharmaceuticals' key executives?
Ritter Pharmaceuticals' management team includes the folowing people:
- Mr. Ira E. Ritter, Co-Founder, Exec. Chairman & Chief Strategic Officer (Age 69)
- Mr. Michael D. Step, CEO & Director (Age 58)
- Mr. Andrew J. Ritter, Co-Founder, Pres, Corp. Sec. & Director (Age 35)
- Dr. Diane J. Plotkin Ph.D., VP of Clinical Devel.
- Mr. Jeffrey Benjamin, Principal Financial & Accounting Officer (Age 53)
When did Ritter Pharmaceuticals IPO?
(RTTR) raised $20 million in an initial public offering (IPO) on Wednesday, June 24th 2015. The company issued 4,000,000 shares at a price of $5.00 per share. Aegis Capital Corp and Chardan Capital Markets acted as the underwriters for the IPO and Barrington Research was co-manager.
Has Ritter Pharmaceuticals been receiving favorable news coverage?
Media coverage about RTTR stock has been trending somewhat positive recently, Accern Sentiment reports. The research group rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ritter Pharmaceuticals earned a media sentiment score of 0.13 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 45.58 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
How do I buy shares of Ritter Pharmaceuticals?
Shares of RTTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ritter Pharmaceuticals' stock price today?
One share of RTTR stock can currently be purchased for approximately $2.96.
How big of a company is Ritter Pharmaceuticals?
Ritter Pharmaceuticals has a market capitalization of $15.21 million. The biotechnology company earns $-7,860,000.00 in net income (profit) each year or ($5.00) on an earnings per share basis. Ritter Pharmaceuticals employs 9 workers across the globe.
How can I contact Ritter Pharmaceuticals?
Ritter Pharmaceuticals' mailing address is 1880 CENTURY PARK EAST SUITE 1000, LOS ANGELES CA, 90067. The biotechnology company can be reached via phone at 310-203-1000 or via email at [email protected]
MarketBeat Community Rating for Ritter Pharmaceuticals (RTTR)
MarketBeat's community ratings are surveys of what our community members think about Ritter Pharmaceuticals and other stocks. Vote "Outperform" if you believe RTTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RTTR will underperform the S&P 500 over the long term. You may vote once every thirty days.
